SCHEMBL7997568

SCHEMBL7997568

CS/C(=N\S(=O)(=O)c1ccc(CCC(C)(C)[Si](O)(c2ccccc2)c2ccccc2)cc1)N1CC2(C=N1)CCCC2

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 18/20 0.38
CNR1 P21554 1/20 0.35
CNR2 P34972 1/20 0.35
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
HTR1A P08908 1/20 0.32
CHRM5 P08912 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32
HTR1D P28221 1/20 0.32
HTR3A P46098 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8001021 0.85 HTR6 (0.44) HTR6CHRM2CHRM4HTR1ACHRM5
SCHEMBL1178900 0.84 HTR6 (0.39) HTR6CNR1CNR2KDM4EALDH1A1
SCHEMBL1178899 0.84 HTR6 (0.39) HTR6CNR1CNR2KDM4EALDH1A1
SCHEMBL12886467 0.80 HTR6 (0.45) HTR6CNR1CNR2
SCHEMBL8000283 0.79 ALDH1A1 (0.53) KDM4EALDH1A1LMNAMAPT
SCHEMBL6885348 0.77 HTT (0.49) HTR6LMNA
SCHEMBL1179248 0.76 HTR6 (0.55) HTR6LMNA
SCHEMBL1179246 0.76 HTR6 (0.55) HTR6LMNA
SCHEMBL1178901 0.76 CNR1 (0.38) HTR6CNR1CNR2KDM4EALDH1A1
SCHEMBL1179015 0.72 HTR6 (0.42) HTR6CNR1CNR2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265589-B1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LTD (BS) 2016-01-27 EP disclosed
US-9126942-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LIMITED (BS) 2015-09-08 US disclosed
US-20150051239-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBVIE BAHAMAS LIMITED (BS) 2015-02-19 US disclosed
US-8901108-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBVIE BAHAMAS LIMITED (BS) 2014-12-02 US disclosed
US-20140011775-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS ABBOTT HEALTHCARE PRODUCTS B.V. (NL) 2014-01-09 US disclosed
US-8563723-B2 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) 2013-10-22 US disclosed
EP-2610247-A1 Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists Abbott Healthcare Products B.V. (NL) 2013-07-03 EP disclosed
WO-2009115515-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS SOLVAY PHARMACEUTICALS B.V. (NL) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051239-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS HTR6, HTR2C, HTR4 HTR6 1/4885CNR1 38/4885CNR2 20/4885
US-20140011775-A1 ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS HTR6, HTR2C, HTR4 HTR6 1/4885CNR1 38/4885CNR2 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.